🚀 VC round data is live in beta, check it out!
Illumina Valuation Multiples
Discover revenue and EBITDA valuation multiples for Illumina and similar public comparables like Sartorius, Exact Sciences, Steris, Zimmer Biomet and more.
Illumina Overview
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Founded
1998
HQ
Employees
10.1K
Website
Financials (LTM)
EV
$21B
Illumina Financials
Illumina reported last 12-month revenue of $4B and EBITDA of $1B.
In the same LTM period, Illumina generated $3B in gross profit, $1B in EBITDA, and $767M in net income.
Revenue (LTM)
Illumina P&L
In the most recent fiscal year, Illumina reported revenue of $4B and EBITDA of $1B.
Illumina expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $767M | XXX | $850M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | — | — | $571M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Illumina Stock Performance
Illumina has current market cap of $20B, and enterprise value of $21B.
Market Cap Evolution
Illumina's stock price is $134.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21B | $20B | 1.3% | XXX | XXX | XXX | $5.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIllumina Valuation Multiples
Illumina trades at 4.9x EV/Revenue multiple, and 17.2x EV/EBITDA.
EV / Revenue (LTM)
Illumina Financial Valuation Multiples
As of April 19, 2026, Illumina has market cap of $20B and EV of $21B.
Equity research analysts estimate Illumina's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Illumina has a P/E ratio of 26.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20B | XXX | $20B | XXX | XXX | XXX |
| EV (current) | $21B | XXX | $21B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 17.2x | XXX | 14.7x | XXX | XXX | XXX |
| EV/EBIT | 20.9x | XXX | 21.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.1x | XXX | 7.4x | XXX | XXX | XXX |
| P/E | 26.6x | XXX | 24.0x | XXX | XXX | XXX |
| EV/FCF | 24.1x | XXX | 22.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Illumina Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Illumina Margins & Growth Rates
Illumina's revenue in the last 12 month grew by 5%.
Illumina's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Illumina's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Illumina's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Illumina Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | (12%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Illumina Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Illumina | XXX | XXX | XXX | XXX | XXX | XXX |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Exact Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| Zimmer Biomet | XXX | XXX | XXX | XXX | XXX | XXX |
| Halma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Illumina M&A Activity
Illumina acquired XXX companies to date.
Last acquisition by Illumina was on XXXXXXXX, XXXXX. Illumina acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Illumina
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIllumina Investment Activity
Illumina invested in XXX companies to date.
Illumina made its latest investment on XXXXXXXX, XXXXX. Illumina invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Illumina
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Illumina
| When was Illumina founded? | Illumina was founded in 1998. |
| Where is Illumina headquartered? | Illumina is headquartered in United States. |
| How many employees does Illumina have? | As of today, Illumina has over 10K employees. |
| Who is the CEO of Illumina? | Illumina's CEO is Jacob Thaysen. |
| Is Illumina publicly listed? | Yes, Illumina is a public company listed on Nasdaq. |
| What is the stock symbol of Illumina? | Illumina trades under ILMN ticker. |
| When did Illumina go public? | Illumina went public in 2000. |
| Who are competitors of Illumina? | Illumina main competitors are Sartorius, Exact Sciences, Steris, Zimmer Biomet. |
| What is the current market cap of Illumina? | Illumina's current market cap is $20B. |
| What is the current revenue of Illumina? | Illumina's last 12 months revenue is $4B. |
| What is the current revenue growth of Illumina? | Illumina revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Illumina? | Current revenue multiple of Illumina is 4.9x. |
| Is Illumina profitable? | Yes, Illumina is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Illumina? | Illumina's last 12 months EBITDA is $1B. |
| What is Illumina's EBITDA margin? | Illumina's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Illumina? | Current EBITDA multiple of Illumina is 17.2x. |
| What is the current FCF of Illumina? | Illumina's last 12 months FCF is $887M. |
| What is Illumina's FCF margin? | Illumina's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Illumina? | Current FCF multiple of Illumina is 24.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.